Martin J Connor,Taimur T Shah,Johanna Sukumar et al. Martin J Connor et al.

Background and objective: Cytoreduction of the primary prostate cancer, involved lymph nodes, and metastases may confer improved cancer control in de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC)....The majority of patients still have viable residual prostate cancer after systemic therapy.

Krishnan R Patel,Melissa Abel,Spyridon P Basourakos et al. Krishnan R Patel et al.

Although radiation therapy has been used as a curative treatment option for patients with localized prostate cancer for decades, there remains a continued need to improve outcomes for patients with localized disease....Systemic therapy in the form of androgen deprivation therapy (ADT) is an important adjunct to radiation therapy which may serve to improve the curative potential of treatment; however, not all forms of systemic therapy which have demonstrated activity in metastatic prostate cancer will improve outcomes...the use of radiation therapy with ADT, androgen receptor signaling inhibitors (ARSIs), chemotherapy, poly(ADP-ribose) polymerase (PARP) inhibitors, immunotherapy, and other small molecule inhibitors is ongoing and will help to define not only which of these may be beneficial for patients localized prostate...cancer but also which patients may be optimal candidates to receive these adjunctive therapies.

Caner Civan,Nika Guberina,Ulrich Krafft et al. Caner Civan et al.

The management of prostate cancer has posed challenges for clinicians in determining optimal treatment strategies. Over the years, various radiopharmaceuticals have been utilized for both the diagnosis and treatment of the prostate cancer.

Jacob Pozin,Menal Bhandari,Luca Valle et al. Jacob Pozin et al.

The detection of local radiorecurrence (LRR) of prostate cancer in the prostate or prostate bed after radiation therapy is increasingly common with the advent of advanced imaging modalities such as the PSMA PET/CT.

Vérane Achard,Alan Dal Pra,Paul Sargos Vérane Achard

Biochemical recurrence (BCR) after radical prostatectomy (RP) remains a clinical challenge, with significant heterogeneity in outcomes and optimal management strategies. Salvage radiotherapy (sRT) is the standard approach, yet the role and ...

Gunhild von Amsberg,Moritz Kaune,Anja Coym et al. Gunhild von Amsberg et al.

Oligometastatic prostate cancer (OMPC) represents an intermediate stage between localized and extensive metastatic disease, characterized by a limited number of metastatic lesions.

Maneesh Singh,Vedang Murthy,Piet Ost Maneesh Singh

Oligometastatic prostate cancer (OMPC), characterized by limited metastatic burden (≤5 lesions), encompasses 3 major subtypes: de novo synchronous oligometastatic hormone-sensitive prostate cancer (om-HSPC), metachronous oligorecurrent HSPC (or-HSPC), and oligoprogressive castrate-resistant prostate...cancer (op-CRPC).

Anna M Dornisch,Tyler M Seibert Anna M Dornisch

Modern trials demonstrate excellent outcomes for men with localized prostate cancer treated with radiation therapy. However, some patients experience recurrences, and more than one-third of recurrences are localized to the prostate.

Amani A Chowdhury,Peter J Hoskin Amani A Chowdhury

Whole gland brachytherapy (BT) boost in combination with external beam radiotherapy (EBRT) improves biochemical relapse free survival (bRFS) for intermediate- and high-risk prostate cancer (PCa).

Michael K Rooney,Zakaria El Kouzi,Ramez Kouzy et al. Michael K Rooney et al.

Prostate cancer is the most commonly diagnosed malignancy among men in the United States, with high-risk localized disease accounting for approximately 15% of new cases. High-risk cancer portends increased risk of locoregional recurrence an...